Binovi Appoints Dr. Michael Gallaway to the Binovi Scientific Advisory Board
TORONTO, ON and NEW YORK, NY / ACCESSWIRE / December 22, 2020 / Binovi Technologies Corp., (Binovi) (OTCQB:BNVIF) (TSX-V:VISN) (GR:2EYA) is proud to announce the appointment of Dr. Michael Gallaway to the Binovi Scientific Advisory Board. Dr. Galloway joins the other members of the board in directing the company's advancements.
"We are very pleased to welcome Dr. Gallaway to the Scientific Advisory Board. His extensive experience working with children will help tremendously as we push Binovi into the education sector, with our focus on K-12 -and particularly K-3-students," said Adam Cegielski, Binovi CEO.
"I am delighted that Dr. Gallaway has joined our Scientific Advisory Board", commented Dr. Leonard Press, Binovi Chief Scientific Officer. "His background in scientific research, vision-based learning problems, vision screening, and concussion management, will help take Binovi to another level."
"I look forward to joining Binovi's Scientific Advisory Board especially as the company is targeting more advanced school screening protocols and interventions for children," said Dr. Gallaway, Binovi Scientific Advisory Board Member.
About Dr. Michael Gallaway
Dr. Gallaway is board certified in vision therapy as a Fellow in the College of Optometrists in Vision Development (COVD), and is a Fellow in the American Academy of Optometry (AAO). He has been in private practice in the South Jersey area since 1989, specializing in vision therapy and children's vision disorders. He is also an Associate Professor at the Pennsylvania College of Optometry at Salus University in Philadelphia. In addition to his teaching, he is involved in research in learning related vision problems, amblyopia, vision therapy for convergence insufficiency, and concussion-related vision problems. He has published many articles in optometric journals and has lectured extensively in the US and internationally on children's vision and vision therapy.
Dr. Gallaway was the Principal Investigator at Salus/PCO for CITT-ART, a National Eye Institute funded nationwide study assessing the impact of vision therapy for convergence insufficiency on reading and attention. In 2015, Dr. Gallaway received the Skeffington Award for Excellence in Optometric Writing from the College of Optometrists in Vision Development in recognition of his scholarly writing and research over his career. Dr. Gallaway was also the Principal Investigator at Salus University for the Convergence Insufficiency Treatment Trial (CITT), an NIH funded randomized multicenter clinical trial that was published in 2008.
Dr. Gallaway was also an Investigator both in his office and at Salus University for the Pediatric Eye Disease Investigator Group (PEDIG) studying the Amblyopia Treatment Studies, which Dr. Gallaway has participated in from 2001 to 2019.
For additional information on the Company, please visit https://www.binovi.com/binovi-connect
@BinoviVISN - Twitter & Instagram
About Binovi Connect
Binovi is digitizing the delivery of healthcare by providing users access to all points of their individual performance from their phone, tablet or desktop computer. Designed for vision optimization and the enhancement of skills related to cognitive performance, Binovi provides measurable results in less time, and with less effort. As a SAAS based solution, the Binovi Connect App is supported by specialized expert knowledge, unique data insights and supporting hardware to deliver customized, one-on-one cognitive training and learning protocols ideal for K-12 Students, Vision Care Specialists, and Sports Performance testing and training. Binovi is currently used in over 20 countries.
Founder | CEO
Dr. Leonard Press
Chief Scientific Officer
Toll-free: 1 (844) 866-6162
Forward looking information:
Certain statements contained in this news release constitute "forward-looking information" as such term is used in applicable Canadian securities laws. Forward-looking information is based on plans, expectations and estimates of management at the date the information is provided and is subject to certain factors and assumptions, including, that the Company's financial condition and development plans do not change as a result of unforeseen events and that the Company obtains regulatory approval. Forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause plans, estimates and actual results to vary materially from those projected in such forward-looking information. Factors that could cause the forward-looking information in this news release to change or to be inaccurate include, but are not limited to, the risk that any of the assumptions referred to prove not to be valid or reliable, that occurrences such as those referred to above are realized and result in delays, or cessation in planned work, that the Company's financial condition and development plans change, and delays in regulatory approval, as well as the other risks and uncertainties applicable to the Company as set forth in the Company's continuous disclosure filings filed under the Company's profile at www.sedar.com . The Company undertakes no obligation to update these forward-looking statements, other than as required by applicable law.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: Binovi Technologies Corp.
View source version on accesswire.com: